<DOC>
	<DOCNO>NCT02621333</DOCNO>
	<brief_summary>This prospective , randomize , open , multicenter phase Ⅱ study evaluate efficacy cytokine-induced killer cell combine chemotherapy stage Ⅳ naive EGFR wild-type lung adenocarcinoma .</brief_summary>
	<brief_title>Chemotherapy Combined Autologous Cytokine-induced Killer Cells Naive Stage IV EGFR-wild Type Lung Adenocarcinoma</brief_title>
	<detailed_description>There still great improvement advance EGFR wild-type lung adenocarcinoma although great progress make treatment non-small cell lung cancer . It 's necessary explore treatment mode kind patient . As progress make tumor immunity immunotherapy , cancer therapist accept treatment model chemotherapy combine immunotherapy . And chemotherapy combine autologous CIK cell one kind common treatment model country . Investigators try evaluate efficacy safety kind treatment model patient stage Ⅳ naive EGFR wild-type lung adenocarcinoma .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Diagnosed stage Ⅳ naive EGFR wildtype lung adenocarcinoma image , tissue and/or cytology ; relapse operation ( patient receive adjuvant chemotherapy interval last chemotherapy relapse least six month . The detection method EGFR mutation ARMS . 2 . EML4ALK fuse gene negative detection EML4ALK FISH ventana IHC . 3 . There least one measurable lesion ( CT MRI ) 4 . No cancer history ( except skin squamous cell carcinoma surgery ) 5 . Age 18 75 year old 6 . World health organization Eastern Cooperative Oncology Group Performance Status 01 7 . Life expectancy 3 month followedup 8 . Patients must adequate organ marrow function define : white blood cell : 3.5×109/L , Neutrophils : 1.5×109/L , Platelets : 80×109/L , Hemoglobin 90g/L , Serum total bilirubin le 1.5 fold upper normal limit ( ULN ) , Serum glutamicoxal ( ) acetic transaminase : le 2.5×ULN ( liver metastasis le 5×ULN ) ; Serum creatinine : le 1.0×ULN , Prothrombin time , Active partial thromboplastin time , Fibrinogen , Thrombin time normal range . 9 . Women childbearing period must take effective contraceptive measure time study . During period study result blood urine pregnancy test negative . 10 . Men take effective contraceptive measure begin therapy one month last cycle chemotherapy . 11 . Willing comply ban constraint study protocol specify . 12 . Informed consent willing participate study . 1 . Accepted study drug 30 day begin study . 2 . Brain metastasis clinical symptom ( exception control radiation ) 3 . Active viral bacterial infection ca n't control appropriate antiinfection treatment 4 . Known HIV infection , syphilis serology reaction positive , active hepatitis B virus hepatitis C virus infection 5 . Suffering mental illness illness , heart lung disease , diabetes , etc . control , cop study treatment monitoring requirement . 6 . Known allergy kind component study drug 7 . Active rheumatic disease 8 . Organ transplant recipient 9 . Poor compliance 10 . Pregnant woman 11 . Lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>